Evidence map›Paper›PMID 28410882›Full record

ArticleExperimental hematology2017

Epo reprograms the epigenome of erythroid cells.

Andrea A Perreault, Mary Lauren Benton, Mark J Koury, Stephen J Brandt, Bryan J Venters

Abstract read
In one paragraph

Article in Experimental hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. STAT5 as a Key Protein of Erythropoietin Signalization.International journal of molecular sciences · 2021
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Andrea A PerreaultDepartment of Molecular Physiology and Biophysics, Chemical and Physical Biology Program, Vanderbilt Genetics Institute, Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN.
Mary Lauren BentonDepartment of Biomedical Informatics, Vanderbilt University, Nashville, TN.
Mark J KouryDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Stephen J BrandtDepartment of Cancer Biology, Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN.
Bryan J VentersDepartment of Molecular Physiology and Biophysics, Chemical and Physical Biology Program, Vanderbilt Genetics Institute, Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN. Electronic address: bryan.venters@vanderbilt.edu.

Funding

MULTIDISCIPLINARY TRAINING IN MOLECULAR ENDOCRINOLOGYT32DK007563 · NIDDK · VANDERBILT UNIVERSITY · PI Richard M O'Brien · 1988 to 2026
$15.9M
NIDDK NIH HHS T32 DK007563
6 · The paper itself

Abstract

The hormone erythropoietin (Epo) is required for erythropoiesis, yet its molecular mechanism of action remains poorly understood, particularly with respect to chromatin dynamics. To investigate how Epo modulates the erythroid epigenome, we performed epigenetic profiling using an ex vivo murine cell system that undergoes synchronous erythroid maturation in response to Epo stimulation. Our findings define the repertoire of Epo-modulated enhancers, illuminating a new facet of Epo signaling. First, a large number of enhancers rapidly responded to Epo stimulation, revealing a cis-regulatory network of Epo-responsive enhancers. In contrast, most of the other identified enhancers remained in an active acetylated state during Epo signaling, suggesting that most erythroid enhancers are established at an earlier precursor stage. Second, we identified several hundred super-enhancers that were linked to key erythroid genes, such as Tal1, Bcl11a, and Mir144/451. Third, experimental and computational validation revealed that many predicted enhancer regions were occupied by TAL1 and enriched with DNA-binding motifs for GATA1, KLF1, TAL1/E-box, and STAT5. Additionally, many of these cis-regulatory regions were conserved evolutionarily and displayed correlated enhancer:promoter acetylation. Together, these findings define a cis-regulatory enhancer network for Epo signaling during erythropoiesis, and provide the framework for future studies involving the interplay of epigenetics and Epo signaling.

Indexed as

AnimalsBasic Helix-Loop-Helix ProteinsCarrier ProteinsCellular ReprogrammingDNA-Binding ProteinsEpigenesis, GeneticEpigenomicsErythroid CellsErythropoiesisErythropoietinFemaleGATA1 Transcription FactorKruppel-Like Transcription FactorsMiceMice, Inbred BALB CMicroRNAsBasic Helix-Loop-Helix ProteinsBcl11a protein, mouseCarrier ProteinsDNA-Binding Proteinserythroid Kruppel-like factorErythropoietinGata1 protein, mouseGATA1 Transcription FactorKruppel-Like Transcription FactorsMicroRNAsMIRN144 microRNA, mouseMirn451 microRNA, mouseNuclear ProteinsProto-Oncogene ProteinsRepressor ProteinsSTAT5 Transcription FactorTal1 protein, mouseT-Cell Acute Lymphocytic Leukemia Protein 1

Identifiers

PMID28410882
PMCPMC5551495

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.